Panmure Gordon Reaffirms Buy Rating for Vernalis plc (VER)
Vernalis plc (LON:VER)‘s stock had its “buy” rating reissued by stock analysts at Panmure Gordon in a report released on Thursday. They currently have a GBX 76 ($0.99) price objective on the stock. Panmure Gordon’s price objective would indicate a potential upside of 70.79% from the stock’s current price.
VER has been the subject of several other reports. Canaccord Genuity reaffirmed a “buy” rating and set a GBX 84 ($1.10) price objective on shares of Vernalis plc in a research note on Tuesday, September 6th. Stifel Nicolaus reiterated a “buy” rating on shares of Vernalis plc in a research report on Friday, June 24th. Shore Capital reiterated a “house stock” rating on shares of Vernalis plc in a research report on Friday, July 8th. Finally, N+1 Singer reiterated a “hold” rating and set a GBX 46 ($0.60) target price on shares of Vernalis plc in a research report on Thursday. One analyst has rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of GBX 73 ($0.95).
Vernalis plc (LON:VER) opened at 40.6875 on Thursday. The company’s market cap is GBX 181.11 million. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 79.00. The stock’s 50 day moving average price is GBX 43.85 and its 200 day moving average price is GBX 45.77.
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.